[
  {
    "ts": null,
    "headline": "Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?",
    "summary": "On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March.  After all, it's been less than a year since regulators in the U.S. and E.U. approved its first therapy, Casgevy, to treat two blood-based disorders.  Casgevy's initial launch hasn't been as exciting as investors and its partner, Vertex Pharmaceuticals (NASDAQ: VRTX), had hoped.",
    "url": "https://finnhub.io/api/news?id=ba407162707fe20834bf3a729ed73de9b2f3bcd2e3b3faad2cf8b70d2d20fc45",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732445220,
      "headline": "Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?",
      "id": 131613817,
      "image": "https://g.foolcdn.com/editorial/images/798604/smart-investor-studying-stock-charts-getty.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March.  After all, it's been less than a year since regulators in the U.S. and E.U. approved its first therapy, Casgevy, to treat two blood-based disorders.  Casgevy's initial launch hasn't been as exciting as investors and its partner, Vertex Pharmaceuticals (NASDAQ: VRTX), had hoped.",
      "url": "https://finnhub.io/api/news?id=ba407162707fe20834bf3a729ed73de9b2f3bcd2e3b3faad2cf8b70d2d20fc45"
    }
  }
]